Expert Ratings for Fate Therapeutics
Within the last quarter, Fate Therapeutics (NASDAQ:FATE) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
Sorrento Therapeutics, Citius Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures traded slightly higher this morning. Here are some big stocks recording losses in today’s pre-market trading session.
5 Cheapest Health Care Stocks You Should Think About
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Dow Jumps 700 Points; S&P 500 Rises Over 2%
U.S. stocks traded higher toward the end of trading, with the Dow Jones gaining around 700 points on Friday.
Nasdaq Gains 1.5%; Fate Therapeutics Shares Plunge
U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 550 points on Friday.
Benzinga’s Top Ratings Upgrades, Downgrades For January 6, 2023
Upgrades Piper Sandler upgraded the previous rating for Aligos Therapeutics Inc (NASDAQ:ALGS) from Neutral to Overweight. Aligos Therapeutics…
Morgan Stanley Maintains Equal-Weight on Fate Therapeutics, Lowers Price Target to $8
Morgan Stanley analyst Michael Ulz maintains Fate Therapeutics (NASDAQ:FATE) with a Equal-Weight and lowers the price target from $35 to $8.
B of A Securities Downgrades Fate Therapeutics to Underperform, Lowers Price Target to $4
B of A Securities analyst Tazeen Ahmad downgrades Fate Therapeutics (NASDAQ:FATE) from Buy to Underperform and lowers the price target from $72 to $4.
Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket
Gainers
OncoCyte Corporation (NASDAQ: OCX) rose 89.2% to $0.70 in pre-market trading. Oncocyte, last month, announced an over 40% reduction of its workforce to realign the team towards key products that address larger markets.
Stifel Downgrades Fate Therapeutics to Hold, Lowers Price Target to $5.3
Stifel analyst Benjamin Burnett downgrades Fate Therapeutics (NASDAQ:FATE) from Buy to Hold and lowers the price target from $107 to $5.3.